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Oxaliplatin (OHP) is an anticancer agent that acts by formation of Platinum-DNA (Pt-DNA) adducts resulting in DNA-strand breaks
and is used for the treatment of colorectal cancer. The pyrimidine analog trifluorothymidine (TFT) forms together with a thymidine
phosphorylase inhibitor (TPI) the anticancer drug formulation TAS-102, in which TPI enhances the bioavailability of TFT in vivo. In this
in vitro study the combined cytotoxic effects of OHP with TFT were investigated in human colorectal cancer cells as a model for TAS-
102 combinations. In a panel of five colon cancer cell lines (WiDr, H630, Colo320, SNU-C4 and SW1116) we evaluated the OHP-
TFT drug combinations using the multiple drug–effect analysis with CalcuSyn software, in which the combination index (CI) indicates
synergism (CIo0.9), additivity (CI¼0.9–1.1) or antagonism (CI41.1). Drug target analysis was used for WiDr, H630 and SW1116
to investigate whether there was an increase in Pt-DNA adduct formation, DNA damage induction, cell cycle delay and apoptosis.
Trifluorothymidine combined with OHP resulted in synergism for all cell lines (all CIo0.9). This was irrespective of schedule in which
either one of the drugs was kept at a constant concentration (using variable drug ratio) or when the two drugs were added in a 1:1
IC50-based molar ratio. Synergism could be increased for WiDr using sequential drug treatment schedules. Trifluorothymidine
increased Pt-DNA adduct formation significantly in H630 and SW1116 (14.4 and 99.1%, respectively; Po0.05). Platinum-DNA
adducts were retained best in SW1116 in the presence of TFT. More DNA-strand breaks were induced in SW1116 and the
combination increased DNA damage induction (420%) compared with OHP alone. Exposure to the drugs induced a clear cell-cycle
S-phase arrest, but was dose schedule and cell line dependent. Trifluorothymidine (TFT) and OHP both induced apoptosis, which
increased significantly for WiDr and SW1116 after TFT–OHP exposure (18.8 and 20.6% respectively; Po0.05). The basal protein
levels of ERCC1 DNA repair enzyme were not related to the DNA damage that was induced in the cell lines. In conclusion, the
combination of TFT with the DNA synthesis inhibitor OHP induces synergism in colorectal cancer cells, but is dependent on the dose
and treatment schedule used.
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Most chemotherapy regimens used in the treatment of colorectal
cancer consist of combinations of drugs to increase the therapeutic
efficacy (Peters et al, 2000). The most common combinations
include the fluoropyrimidine 5-fluorouracil (5FU) (Pinedo and
Peters, 1988; Schmoll et al, 1999; Fishman and Wadler, 2001),
together with irinotecan (CPT-11) and oxaliplatin (OHP) or more
recently several targeted agents (Grivicich et al, 2001; Coutinho
and Rocha Lima, 2003). For the platinum (Pt) analogue, OHP
synergism with 5FU and leucovorin (LV) has been shown, whereas
the drug shows little toxicity overlap and the combination has
superior activity compared to 5FU/LV alone. Oxaliplatin is
combined with 5FU/LV (FOLFOX and FLOX) regimens (Pelley,
2001; Andre and De Gramont, 2004; Wolmark et al, 2005), or in
combination with the 5FU prodrug capecitabine (XELOX) (Cassidy
et al, 2004) or CPT-11 (Goldberg et al, 2004).
Oxaliplatin is also active against other malignancies (Raymond
et al, 1998c), and additive or synergistic effects with other
anticancer drugs can be induced (Raymond et al, 2002).
Oxaliplatin has distinct biochemical, pharmacological and cyto-
toxic properties compared with the related platinum compounds
cisplatin and carboplatin (Rixe et al, 1996) and shows no
crossresistance. All platinum compounds are cell cycle phase
nonspecific and undergo nonenzymatic conversion to their active
derivatives. They can react with DNA mainly by formation of Pt-
DNA intrastrand adducts, and also by formation of interstrand and
DNA–protein crosslinks, thereby blocking DNA replication and
transcription (Raymond et al, 1998b; Woynarowski et al, 2000).
Unlike the former two agents, OHP carries the diaminocyclo-
hexane (DACH) ligand, which allows DNA lesions to avoid DNA
mismatch repair and DNA damage recognition pathways (Fink
et al, 1996; Vaisman et al, 1998). The formation of DACH-Pt-DNA
adducts eventually results in DNA-strand breaks leading to the
induction of apoptosis (Faivre et al, 2003; Arango et al, 2004). As
5FU resistance is regularly observed, other combinations enhan-
cing OHP are of major interest to bypass 5FU resistance.
Murakami et al (2000) previously showed that the fluoropyrimi-
dine trifluorothymidine (TFT; trifluridine) was able to exert
cytotoxicity against 5FU-resistant DLD-1 colon cancer cells.
Trifluorothymidine (TFT) is currently used as an antiviral
agent (De Clercq, 2004) and is part of the novel oral antitumour Revised 3 November 2006; accepted 22 November 2006
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sdrug preparation TAS-102 (Emura et al, 2004b; Tsuchiya et al,
2004; Temmink et al, 2005), which also consists of the
antiangiogenic thymidine phosphorylase inhibitor TPI (Matsushita
et al, 1999; Fukushima et al, 2000; Takao et al, 2000). TAS-102
is currently evaluated in different treatment schedules in phase
I clinical trials (Hong et al, 2006). Trifluorothymidine acts
by incorporation into DNA leading to DNA-strand breaks
(Emura et al, 2004c), and by inhibition of thymidylate synthase
(TS) (Eckstein et al, 1994; Temmink et al, 2004; Temmink
et al, 2005), one of the major rate-limiting enzymes in DNA
synthesis. In contrast to 5FU, TFT is not incorporated into RNA
and does not need folates to form a ternary complex with TS.
Trifluorothymidine is converted by thymidine kinase (TK) to 5-
trifluoro-20-deoxythymidine-50-monophosphate (TF-TMP), which
binds covalently to the active site of TS to inhibit its activity
(Eckstein et al, 1994; Santi and Sakai, 1972). Thymidylate synthase
inhibition results in an induction of a series of downstream events,
eventually leading to cell death (Van Triest et al, 2000). These
properties make TFT a suitable candidate to be combined
with OHP, as both agents cause DNA damage and incorpora-
tion of TFT into DNA opposite to adenosine might affect the
A-A-adduct formations.
In various colorectal cancer cell lines, we evaluated the
interaction between the dual-targeted TFT and OHP in relation
to formation of Pt-DNA adducts and the induction of DNA-strand
breaks, cell cycle delay and apoptosis.
MATERIALS AND METHODS
Materials
Dulbecco’s modified Eagle’s medium (DMEM) and Hepes buffer
were purchased from Cambrex BioScience (Verviers, Belgium) and
foetal bovine serum (FBS) from Greiner Bio-One (Frickenhausen,
Germany). Trifluorothymidine (TFT) was synthesised and pro-
vided by Taiho Pharmaceuticals Co. (Tokushima, Japan). Oxali-
platin was a gift from Sanofi-Synthelabo Inc. (Lyon, France).
Sulforhodamine B (SRB) protein dye and propidium iodide (PI)
were purchased from Sigma-Aldrich Chemicals (Zwijndrecht, The
Netherlands). Bovine serum albumin (BSA) was obtained from
Merck (Darmstadt, Germany). The PVDF membranes, ECL
Hyperfilms and ECL Plus detection kit were obtained from
Amersham Biosciences (Buckinghamshire, UK). The primary
antibodies mouse-anti-human MLH1, MSH2, ERCC1 and
b-tubulin were purchased from Zymed Lab Inc. (San Francisco,
CA, USA), Oncogene Research Products (Cambridge, MA, USA),
NeoMarkers Inc. (Fremont, CA, USA) and BD Biosciences (San
Jose, CA, USA), respectively. The secondary peroxidase-conjugated
antibodies were purchased from DAKO (Glostrup, Denmark).
All other chemicals were of analytical grade and commercially
available.
Cell culture
The colorectal cancer cell lines WiDr, H630, Colo320, SNU-C4 and
SW1116 were used in this study. WiDr, Colo320 and SW1116 were
obtained from the American Type Culture Collection (ATCC);
H630 and SNU-C4 were a kind gift from Dr PG Johnston (at that
time at the National Cancer Institute, Bethesda, MD, USA). All
these cell lines were cultured in DMEM supplemented with 10%
heat-inactivated FBS and 20mM Hepes buffer (without antibiotics).
They were grown as adherent monolayers in a humidified
atmosphere containing 5% CO2 at 371C and were maintained in
exponential growth. All cell lines except SNU-C4 are p53 mutated
where no or decreased induction of p53 expression is present
(Peters et al, 2002).
Growth inhibition experiments and multiple drug-effect
analysis
To assess cytotoxicity of the cell lines to the drugs the SRB
cytotoxicity assay was used (Skehan et al, 1990; Keepers et al,
1991). In brief, the cells were seeded in 100ml medium in triplicate
in 96-well flat-bottom plates (Greiner Bio-One, Frickenhausen,
Germany) in different densities depending on their growth rate
(5000–10000cellswell
 1). After 24h, 100ml drug containing
medium was added to the wells and the cells were incubated for
another 72h. Thereafter, cells were fixed using trichloro-acetic acid
(TCA) and stained with the SRB dye. Differences in optical density
(OD measured at 540nm) between the treated cells and untreated
control cells were compared. The percentage of control growth at
the start and end of drug exposure was calculated using the
formula: [(ODtreated/ODstart drug exposure) 1]/[(ODcontrol/ODstart drug
exposure) 1] 100%. The obtained IC25 and IC50 values were
expressed as the concentrations that corresponded to a reduction
of cellular growth by 25 and 50%, respectively, when compared
with values of the untreated control cells.
All cell lines were exposed to the drugs alone or in combination.
Different combination variants were used to test the interaction
of the drugs: either one drug was added at a concentration that
caused 25% growth inhibition and the other drug was added in a
concentration range, or both drugs were added in a fixed IC50-
based molar ratio. To evaluate the effect of a combination of two
drugs, CalcuSyn (Version 1.1.1 1996, Biosoft, Cambridge, UK) was
used, a program based on the method of Chou and Talalay (Chou
and Talalay, 1984). The multiple-drug effect analysis provides a
numerical, statistically evaluable method, and provides classical
isobolograms which give information on synergism, but no
quantification.
The absorbance values of drug treated wells were compared to
the absorbance values of the control wells to calculate each fraction
affected (FA), where FA¼0.25 means a decrease in absorbance
and growth of 25%. From the median drug–effect plots the dose
that reduced absorbance by 50% (Dx) and the slope were
calculated, after which the doses of the separate drugs and
combination required to induce various levels of cytotoxicity
were calculated (Temmink et al, 2006). For each level of
cytotoxicity, a mutually nonexclusive combination index (CI)
was calculated using the formula CI¼[(D)1/(D1 FA)1]þ[(D)2/
(D1 FA)2]þ[a(D)1(D)2/(D1 FA)1(D1 FA)2]. The parameters (D)1
and (D)2 represent the doses of the combination of drugs in a
fixed ratio, whereas (D1 FA)1 and (D1 FA)2 are the doses of the
individual drugs resulting in the effect 1 FA (a¼1 for mutually
nonexclusive drugs). The CI indicates synergism (CIo0.9),
additivity (CI¼0.9–1.1) or antagonism (CI41.1). A mean CI
was calculated from data points with FA40.5 for the combinations
in which one drug was added at a constant concentration, and
from the FA values 0.6, 0.75 and 0.9 for the fixed ratio
combinations. The FA range used to calculate the average CI
values in the combination experiments did not include CI values of
FAo0.5, which was considered as not relevant growth inhibition
(Peters et al, 2000), because one aims to achieve the maximal effect
of the drugs tested on cancer cells. Furthermore, CI values at
FA40.9 were not taken into account owing to higher chance to
subject to error, and because this would not add much more
information. Averaging the CI values for the whole FA¼01–0.9
range might also lead to false interpretation of the data, and
different effects were seen at different FA values (Figure 2B).
Determination of platinum-DNA adduct formation
The formation of Pt-DNA adducts into DNA after exposure of cells
to OHP was measured using a protocol adapted from Van Moorsel
et al (1999). Cells were grown to 70–80% confluence in 75cm
2
tissue culture flasks (Greiner Bio-One) and then treated with
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s200mM OHP for 24h at 371C, either alone or in combination with
10mM TFT (4h preincubation or/and simultaneous exposure), to
investigate whether TFT influenced Pt-DNA adduct formation
induced by OHP. Thereafter, the cells were either harvested or
cultured in drug-free medium for another 3h. After washing with
phosphate-buffered saline (PBS), trypsinising and harvesting the
cells, the cell pellets (at least 5 10
6 cells) were resuspended in ice-
cold DNA STAT-60 lysis reagent (Tel-Test Inc., Friendswood, TX,
USA; 5 10
6cells1ml
 1). The DNA extraction, precipitation and
washing steps were carried out according to the protocol of the
manufacturer. The obtained DNA pellets were dissolved in a TE
buffer (10mM Tris, 1mM EDTA; pH 8.0). DNA content was
estimated by measuring optical densities with the NanoDrop
apparatus (NanoDrop Technologies Inc., Wilmington, DE, USA).
All samples had an OD260/OD280 ratio41.9 indicating uncontami-
nated DNA. Sodium chloride (1.65 M) was added in a volume of 0.1
to the dissolved DNA. A calibration curve was made using different
solutions of OHP (0–2mM). The Pt content of the samples and
standards (expressed as pmolmg
 1 DNA) was measured using
Atomic Absorption Spectrometry (AAS).
Comet DNA damage assay
The alkaline comet assay or single-cell gel electrophoresis assay
was performed to detect DNA-strand breaks associated with DNA
damage (Olive and Banath, 1997; Olive, 2002). The assay is based
on the alkaline lysis of labile DNA at damaged sites where
denatured and cleaved DNA fragments migrate easily out of the
cell under the influence of an electric field than undamaged DNA.
To study the role of DNA damage in the interaction between OHP
and TFT, we exposed 1.6 10
5 cells in six-well plates to IC90 of the
drugs for 24h. This concentration caused 90% growth inhibition in
the 72h growth inhibition studies. As positive controls, cells were
exposed to 100mM H2O2 for 20min at 41C to induce significant
oxidative damage. Untreated cells were used as negative controls.
The cell suspensions consisted of 8 10
4cellsml
 1 in PBS. The
lysis, electrophoresis and staining procedures were previously
described (Hartley et al, 1999).
After the PI staining procedure, the slides were rinsed in
distilled water and viewed within 24h. The DNA from the cells was
visualised using a Zeiss Axioskop2 fluorescence microscope (Carl
Zeiss Mikroscopie, Jena, Germany) with a Zeiss HBO-103W/2
mercury light source (using 546nm light excitation filter). The
microscope was attached to a Zeiss AxioCam MRm Camera using
an Achroplan  20 objective. The obtained comet images were
analysed using Scion Image software (Scion Corp., Frederick, MD,
USA). DNA damage was quantified as the tail moment, the product
of the percentage of total DNA in the comet tail and the mean
distance between the head and tail distributions (Hartley et al,
1999). At least 20 comets were analysed per slide.
Apoptosis analysis
The terminal deoxynucleotidyl transferase (-TdT-)mediated dNTP-
labelling (TUNEL) method was used for the detection of cells
undergoing apoptosis. For this purpose we used the TdT-DNA-
Fragment End Labeling Kit (FragELt; Calbiochem, Oncogene
Research Products, Cambridge, MA, USA). In this method, TdT
binds to exposed 30-OH ends of DNA fragments generated in
apoptotic cells in order to add biotin-(un)labeled dNTPs, which
are detected using a streptavidin–horseradish peroxidase con-
jugate. Cells were plated into 6-wells plates as described in the cell
cycle analysis section and were exposed 48h or 72h to IC75 of OHP
or/and TFT (with or without a 24h TFT preincubation period).
After the incubation period cytospin slides were made using a
formaldehyde fixation protocol. The staining was performed
according to the manufacturer’s recommended procedure. Cells
stained positive with 30-30-diaminobenzidine (DAB) produce a
brownish colour, whereas nonreactive cells were counterstained
with methylgreen. Actinomycin D-treated HL60 cells were
included in the kit and served as positive controls. Negative
controls were cytospins of untreated cells in their logarithmic
growth phase. Using light microscopy, 1000 cells were counted
twice for positive/negative staining on randomly selected areas on
the glass slide, and the apoptotic index was calculated as the
percentage of positive staining cells. Cells were defined as
apoptotic when the (major part of) nuclear area was DAB-labelled.
Cell cycle analysis
Cell cycle distribution was measured on cells exposed to the drugs
alone or in combination (Cloos et al, 2002). On day 0, a series
of six-well plates were filled with 2ml cell suspensions at a
concentration of 2 10
5 cellswell
 1. After 24h incubation, cells
were exposed 48h to IC50 or IC75 concentrations of the drugs alone
or in combination (with or without a 4h TFT preincubation
period). Pilot experiments demonstrated that the optimal exposure
time was 48h. The percentage of cells in the different cell cycle
phases (G1, S and G2M) was measured using FACScan (Becton
Dickinson Immunocytometry Systems, San Jose, CA, USA). For
each measurement, 20000 cells were counted, and each sample was
assayed in duplicate. For calculation of the cell cycle distribution,
the Becton Dickinson’s CellQuest software was used.
Western blot analysis
Frozen pellets of the cell lines were lysed in buffer (0.1% Triton X-
100, 150mM NaCl, 10mM Tris-HCl, 50mM b-glycerophosphate; pH
7.5) and sonificated 5 5s with 5s intervals. After centrifugation
(10min 13000g at 41C), the supernatants were measured for
protein content using the BioRad Bradford protein assay
(Bradford, 1976). For determination of protein expression, 20mg
of total protein from each cell line was loaded and separated on a
10% SDS-PAGE gel, followed by blotting on a PVDF membrane.
Each membrane was preincubated O/N at 41C with blocking buffer
(5% milk powder in 0.15 M NaCl, 0.05% Tween-20, 10mM Tris-HCl
(TBS-T); pH 8.0) to prevent aspecific antibody binding. This was
followed by 2h incubation at room temperature with the primary
antibodies diluted in TBS-T containing 5% BSA. After three 10min
washing steps with TBS-T, the blots were incubated for 1h at room
temperature with the secondary antibodies diluted in TBS-T
containing 2% milk powder. Detection of antibody binding was
measured with enhanced chemoluminescence (ECL Plus detection
solution and ECL Hyperfilms). Protein levels were determined by
densitometric scanning.
Statistical evaluation
The (un)paired Student’s t-test was used for statistical evaluation
of the results. Changes were considered to be significant when
Po0.05.
RESULTS
Evaluation of the combination OHP with TFT
The sensitivities of the colorectal cancer cell lines for OHP and TFT
varied considerably (Table 1). SNU-C4 was most sensitive to OHP;
H630 and Colo320 were most sensitive to TFT. WiDr was most
resistant to OHP, whereas SW1116 was the most TFT-resistant cell
line. The obtained IC50 values were also used to calculate the drug
ratios for the fixed ratio combinations.
Multiple drug-effect analysis was performed for the combina-
tions of TFT with OHP using the CalcuSyn software. Figure 1
shows representative growth inhibition curves with SW1116 cells
for the combinations using a variable concentration of OHP and a
OHP-induced cytotoxicity to colorectal cancer cells
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sfixed concentration of TFT, illustrating at least additive cyto-
toxicity. Dose–effect and FA-CI plots illustrating the effects of
TFT–OHP fixed drug ratio combinations are depicted in Figure 2.
Figure 2A depicts growth inhibition curves of H630 cells exposed
to OHP and TFT at various concentrations based on a 1:1 IC50
ratio, and clearly shows that the combination causes more growth
inhibition than each drug alone. To indicate the effects at different
FA values average CI values were calculated for each FA. Figure 2B
shows the mathematical analysis of these data and demonstrates
synergism at FA40.5 for H630, as well as the other cell lines. The
FA values were obtained after exposure of cells to a series of drug
concentrations of TFT and/or OHP, depending on the combination
variant. The mean CI values of the fixed ratio TFT–OHP
combination variants are shown in Figure 3. The effects of these
combinations were synergistic in the cell lines (all CI o 0.9). For
the variable drug ratio combinations, only in Colo320 (TFTc; mean
CI¼0.9870.08) and SNU-C4 (OHPc; mean CI¼0.9470.16) the
interaction between the drugs was not more than additive. The
extent of synergism differed according to the cell line and
combination variant. Strongest synergism was observed with
SW1116 cells for all three combination variants (0.43pmean
CIp0.64). For further evaluation of the TFT–OHP combination,
only the cell lines WiDr, H630 and SW1116 were used, because
for these cell lines large differences in drug sensitivity were
found. Incubating these cells the first 24h with only TFT or OHP
decreased synergism for the 1:1 ratio combinations for H630 and
SW1116 (0.6pmean CIp1.2; data not shown), but not for WiDr,
where increased synergism was observed for both sequential
combinations (Figure 4); TFT preincubation decreased the mean
CI to 0.6 compared to the simultaneous combination (mean
CI¼0.8170.06), whereas OHP preincubation decreased the mean
CI to 0.4.
Formation of Pt-DNA adducts
Because the synergism might be related to an influence of TFT on
OHP-induced DNA damage by affecting the accumulation of
Pt-DNA adducts, we studied the formation and retention of Pt-DNA
adducts in three cell lines. The cell lines were selected, because one
is rather insensitive to OHP (WiDr) or TFT (SW1116) or sensitive
to both drugs (H630). As WiDr and SW1116 have an intermediate
sensitivity to the other drugs, we reasoned that this panel would be
representative for all five cell lines, also because the synergism
patterns were similar. The measurements were limited to Pt-DNA
adduct formation. Total uptake of OHP in cells was not measured,
as it was considered unlikely that a nucleoside analogue would
affect uptake of a platinum compound into a cell, because
transport mechanisms for platinum analogs are not affected by
nucleoside analogs, but Pt-DNA adduct formation and repair are
(Bergman et al, 1996; Van Moorsel et al, 1999; Yang et al, 2000).
With OHP alone adduct formation ranged from 1.8 to
2.6pmolmg
 1 DNA (Figure 5). Pretreatment with 10mM TFT
decreased the formation of Pt-DNA adducts by 13% or more.
Simultaneous treatment resulted in a significant increase in the
formation of Pt-DNA adducts in H630 and SW1116 (14.4 and
99.1%, respectively; Po0.05), but not in WiDr. However, TFT
Table 1 Growth inhibition of TFT and OHP for the colorectal cancer
cell lines
Cell line TFT OHP
WiDr 20257527
a 60007577
H630 4537114
a 773737
Colo320 5337133
a 20837309
SNU-C4 8307214 30874
SW1116 745071340 11287189
Cells were exposed to a concentration range of TFT or OHP for 72h. Values (IC50 in
nM) are means7s.e.m. of 3–5 experiments
aResults are partly published (Temmink
et al, 2005). 0.03 0.1 1 10 50
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Figure 1 Representative growth inhibition curves for the combination
OHP-TFT using a variable drug ratio. SW1116 cells were exposed 72h to
OHP, TFT or OHPþTFT in which OHP was added at various
concentrations (OHPv) and TFT was kept at a constant IC25 concentration
(TFTc). Filled circles and solid line, OHPv; filled triangles and broken line,
expected growth inhibition calculated from the single drug doses; filled
squares and solid line, OHPvþTFTc. The growth inhibition curves were
obtained from three separate experiments. Per experiment, an average CI
value was calculated from all data points with FA40.5. In this example,
mean CI¼0.64. All s.e.m. values o10%.
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Figure 2 Illustrative growth inhibition curves (A) and FA-CI plots (B) for
the combination OHP-TFT using a fixed drug ratio. Figure A: H630 cells
were exposed 72h to TFT (filled circles), OHP (filled triangles) or
TFTþOHP (filled squares). Figure B: Average CI values calculated from
each FA for all five cell lines used in the study. Per experiment, an average
CI value was calculated from data-points with FA¼0.6, 0.75 and 0.9. All
s.e.m. values of data points o15%.
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spretreatment decreased the Pt-DNA adduct formation (46%). The
formed Pt-DNA adducts after exposure to OHP alone were best
retained in the SW1116 cells (81.6%) compared with H630 and
WiDr (o 56%), and TFT treatment increased this in the latter two
cell lines (410%).
Formation of DNA-strand breaks and induction of
apoptosis
Using the comet assay, we evaluated whether more DNA damage
was induced in the cells after 24h exposure to a combination of
TFT–OHP at their IC90 concentrations compared to each drug
alone (Figure 6). The WiDr, H630 and SW1116 cell lines were used
because the combinations induced synergistic cytotoxicity in these
cells. Relatively high concentrations of the drugs were chosen to
determine the potency of this combination to induce DNA damage
in the cells. The calculated tail moment represents DNA-strand
break formation induced by the drugs. At equally growth
inhibitory concentrations there was consistently more DNA
damage in the cells after exposure to OHP compared to TFT,
although not significantly (P40.05). About 20–30% more DNA
WiDr
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Figure 3 Synergy analysis of OHP combined with TFT for the colorectal
cancer cell lines. Interpretation of CI values: CIo0.9 means synergism;
CI¼0.9–1.1 means additive; CI41.1 means antagonism. TFTc: combina-
tion of the drugs in which TFT was kept at a constant concentration (IC25);
OHPc: combination of the drugs in which OHP was kept at a constant
concentration (IC25); 1:1 ratio: the two drugs were added in a fixed 1:1
IC50-based molar ratio. A mean CI was calculated from data points with
FA40.5 for the combinations with variable drug ratio, and from the FA
values 0.6, 0.75, 0.9 for the fixed ratio combinations. Values (mean
CI7s.e.m.) are based on 3–4 separate experiments. See also Materials and
Methods.
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Figure 4 Representative growth inhibition curves for simultaneous and
sequential OHP-TFT combinations using a fixed drug ratio. WiDr cells
were exposed 72h to OHP with or without TFT in different schedules:
TFT alone (filled circles), OHP (filled triangles), TFTþOHP (filled squares),
24h TFT alone 448h TFTþOHP (filled diamonds), 24h OHP alone
448h TFTþOHP (filled crosses). The growth inhibition curves were
obtained from 3–5 separate experiments (all s.e.m. values o15%). Per
experiment an average CI value was calculated from all data points with
FA40.5.
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Figure 5 Pt-Adduct formation in DNA after exposure of WiDr, H630
and SW1116 cells to OHP with or without TFT in different schedules. The
cell lines were exposed 24h to 200mM OHP alone or with 10mM TFT,
either simultaneously and/or with a 4h preincubation period (preTFT). To
determine retention of the formed Pt adducts the cells were incubated an
additional 3h in drug-free medium (DFM). Values are Means7s.e.m.
(n¼4). *Po0.05 compared to 24h OHP. nd¼nothing detected.
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sdamage was induced after exposure to TFT–OHP compared to
OHP alone. Most DNA-strand breaks were induced in SW1116
cells (mean tail moment of 15.870.5). Comparable results were
seen after exposure to IC75 concentrations of the drugs (all mean
tail moments o 10; data not shown).
Table 2 summarises the results of apoptosis induction using the
TUNEL apoptosis assay when the cells were exposed 72h to IC75
concentrations of the drugs. In the control samples, less than 3%
apoptosis was found in the total cell population. When the cells
were exposed to OHP alone or TFT alone, about equal amounts of
apoptosis were induced (range 6.7–16.2% apoptotic cells). This
was at least 3.7-fold higher compared with the controls. After
TFT–OHP drug treatment most apoptosis was induced in the
WiDr and SW1116 cell populations (18.8 and 20.6%, respectively),
with less in H630 cells; in each cell line, TFT–OHP induced
significantly more apoptosis compared with OHP alone (Po0.05).
Shortening the total exposure to OHP by 24h decreased the
induction of apoptosis by at least 30% for all cell lines. A TFT pre-
exposure period of 24h, followed by 48h OHP exposure, increased
apoptosis induction slightly compared to 48h OHP exposure, but
this was still significantly lower compared with 72h TFT–OHP
exposure (at least 45%; Po0.01). Induction of apoptosis was
generally in agreement with the results obtained from the DNA
damage experiments.
Induction of cell cycle arrest
The combination TFT–OHP was also evaluated using flow
cytometry analysis to determine the cell cycle distribution after
48h drug(s) exposure (Table 3). This time point was chosen
because at 48h substantial changes can be seen in cell cycle
distribution, which are not yet observed after 24h exposure.
Trifluorothymidine induced an S-phase arrest, or G2M-phase
arrest, although this was concentration-, schedule- and cell line-
dependent. In all cell lines TFT or OHP induced a clear reduction
in the G1-phase cell population, probably owing to DNA synthesis
inhibition. This was more pronounced after TFT exposure than
after OHP exposure. For all three cell lines a significant increase
in the S phase cell population was seen after exposure to TFT or
OHP alone (6.2–44.7%; Po0.05). Only in WiDr cells TFT induced
a clear S-phase arrest whereas OHP induced a G2M-phase
arrest (both450%). The combination TFT–OHP induced a strong
S-phase arrest for all cell lines (Po0.01). Compared to OHP
exposure, the combination significantly increased the S-phase cell
population for WiDr and H630, in contrast to SW1116, where TFT
did not increase (%) cells in the S-phase, but (%) cells in G2M
phases was increased from 27.8% to 38.1% (Po0.05). The G1
population was also more decreased (X6.2%). A 4h TFT
preincubation period hardly affected cell cycle distribution
induced by OHP, except for SW1116, where G2M population
increased from 27.8 to 51.3%; (Po0.01). Surprisingly, this result
was not observed in the growth inhibition and apoptosis
experiments. Comparable results were obtained when cells were
exposed to IC50 concentrations of the drugs, but induction of S-
phase arrest was less potent (data not shown).
Protein levels of DNA repair enzymes
Figure 7 shows the basal expression of ERCC1, MLH1 and MSH2
DNA repair proteins for the colorectal cancer cell lines. There was
no direct correlation with OHP or TFT sensitivity. For example,
SW1116 is more sensitive to the drug combination compared to
WiDr, inducing significantly more DNA-strand breaks in these
cells, but also has higher ERCC1 levels, which is part of the DNA
excision repair system, which is mainly involved in the repair of
OHP-induced DNA damage.
DISCUSSION
In the present study we demonstrated synergism between OHP and
TFT, which was found for drug combinations using either variable
or fixed drug ratios. The most pronounced effects were seen in
SW1116 cells, where strong synergism was induced at high effect
levels. There is a parallel enhancement of OHP-induced DNA
damage and apoptosis by TFT. We have demonstrated that this
damage may be explained by increased formation of Pt-DNA
adducts, which possibly is related to increase incorporation of TFT
into the DNA.
The platinum compound OHP is currently routinely used in the
treatment of colorectal cancer patients in combination with 5FU
(or its prodrug capecitabine). In the case of 5FU resistance, it may
also be combined with irinotecan (CPT-11), thereby improving
response and survival rates (Maindrault-Goebel et al, 1999;
Coutinho and Rocha Lima, 2003; Andre and De Gramont, 2004;
Smorenburg et al, 2006). Oxaliplatin acts by effectively disrupting
the DNA replication and transcription in the cell, but the
downstream molecular events underlying its mechanism of
action have not been characterised very well (Arango et al,
02468 1 0 1 2 1 4 1 6 1 8
TFT
OHP
TFT+ OHP
TFT
OHP
TFT+ OHP
TFT
OHP
TFT+ OHP
Tail moment
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H630
SW1116
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**
Figure 6 DNA damage induction in WiDr, H630 and SW1116 cells
using the Comet assay. The cells were exposed 24h to [IC90] OHP or
[IC90] TFT alone or in combination. These concentrations were: WiDr:
75mM TFT, 75mM OHP; H630: 50mM TFT, 30mM OHP and SW1116:
200mM TFT, 80mM OHP. Values are means7s.e.m. (n¼3). Significant
differences compared with OHP alone: *Po0.05; **Po0.01 (paired t-test).
Table 2 Induction of apoptosis by OHP, TFT or both drugs in WiDr,
H630 and SW1116 cells
Cell line
Drug Treatment WiDr H630 SW1116
Control 2.370.6** 1.670.3** 2.970.2**
TFT IC75 72h 16.272.5 6.770.5** 10.671.7
OHP IC75 72h 13.271.7 8.273.0 13.772.2
OHP IC75+TFT IC75 72h 18.873.1* 13.171.0* 20.671.5**
OHP IC75 48h alone 8.971.2* 3.570.3** 7.070.7**
TFT IC75 24h4OHP IC75 48h 9.371.1* 7.070.7* 9.070.9*
The cells were exposed 72h to [IC75] of the drugs, either alone or in combination.
These concentrations were: WiDr: 25mM TFT, 10mM OHP; H630: 10mM TFT, 3.5mM
OHP and SW1116: 100mM TFT, 10mM OHP. Values (%) represent [apoptosis
population]/[total cell population] and are expressed as means7s.e.m. (n¼3).
Compared to OHP alone: *Po0.05; **Po0.01 ((un)paired t-test).
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s2004). Oxaliplatin (OHP) itself reduces growth of the cells at
clinically relevant concentrations, which can be associated with a
G2M-phase arrest in the cell cycle (Raymond et al, 2002) and
increased induction of apoptosis (Tassone et al, 2002). Inducing
cell death by chemotherapeutics is an important terminal
mechanism to eliminate malignant cells in vivo (Broker et al,
2005). Trifluorothymidine was able to enhance OHP-induced
apoptotic cell death, possibly owing to extensive DNA damage
induction by increased Pt-DNA adduct formation.
In preclinical studies using colorectal cancer cells, OHP has been
combined with a variety of anticancer metabolites to improve its
killing efficacy, such as TS inhibitors (Raymond et al, 1997),
taxanes and topoisomerase I inhibitors (Raymond et al, 1998a;
Raymond et al, 2002). Trifluorothymidine, in the form of the orally
administered TAS-102 formulation, might be a good alterntive to
5FU in the combination with OHP. Trifluorothymidine incorpora-
tion into DNA also induces DNA-strand breaks, and as a result
of intracellular thymidine depletion owing to inhibition of TS,
misincorporation of uracil into DNA occurs, thereby enhancing
the induction of DNA damage (Webley et al, 2001). Trifluorothy-
midine itself is a dual-targeted agent, and the other part of
TAS-102 is TPI, which is a potent TP inhibitor (Ki¼0.17nM)
(Fukushima et al, 2000). In vivo, TFT is very dependent on TP
activity, since adding TPI enhances bioavailability of TFT (Emura
et al, 2005), which may favour the combination OHP-TFT, possibly
leading to more DNA damage in cells and higher cytotoxicity.
Secondly, TP is also known as PD-ECGF (Moghaddam and
Bicknell, 1992; Sumizawa et al, 1993), which has stimulating
properties on blood vessel formation in solid tumours (Takahashi
et al, 1998). Previous studies showed that TPI inhibits blood vessel
formation, thereby increasing apoptosis (Matsushita et al, 1999)
and suppressing the formation of metastases (Takao et al, 2000). In
contrast to 5FU-based formulations, the orally given TAS-102 has
both cytotoxic and antiangiogenic properties.
Trifluorothymidine and 5FU are both potent TS inhibitors, but
in contrast to TFT, 5FU is also incorporated into the RNA of
cancer cells (Peters, 2002). Furthermore, TFT can only be activated
by TK, thus decreased TK activity will affect TFT conversion to
TF-TMP, and subsequently leads to decreased TS inhibition and
TF-TTP incorporation into the DNA (Temmink et al, 2005). 5-
fluorouracil can be anabolised to its active forms in two alternative
pathways next to TK activation by uridine phosphorylase or
orotate phosphoribosyltransferase, which seem the most important
pathways (Peters, 2002). On the other hand, TFT is activated
rapidly because it only needs one phosphorylation step in contrast
to 5FU, and therefore TFT can be active against 5FU-resistant
colorectal cancer cells (Murakami et al, 2000; Emura et al, 2004a).
Thus, compared with 5FU, TFT is clearly a different drug than 5FU
leading to different drug interactions. In general, 5FU combina-
tions with cisplatin show variable interactions (Van der Wilt et al,
1992), whereas combinations of 5FU with OHP in general lead to
synergistic interactions (Fischel et al, 1998). Our data clearly show
synergism of TFT with OHP in all conditions.
Our data allow some preliminary conclusions about appropriate
scheduling of OHP and TFT. Ideally, a combination should be at
least additive in its anticancer effects but without excessive normal
tissue toxicity. Oxaliplatin is administered by infusion, and in
animals TAS-102 is orally administered and is most effective when
used as a multiple daily dosing schedule (three times daily at
150mgkg
 1day
 1) (Emura et al, 2004b,c). In human tumour
Table 3 Cell cycle distribution of WiDr, H630 and SW1116 cells following OHP and/or TFT exposure
Cell cycle distribution
Drug treatment (%) G1 (%) S (%) G2M
WDr
Control 46.873.0 15.270.9 38.072.9
OHP IC75 48h 25.872.6 21.471.8 52.873.9
TFT IC75 48h 3.470.6** 59.973.4** 36.773.1*
TFT IC75+OHP IC75 48h 18.174.1 53.476.0** 28.573.1**
preTFT4OHP IC75 48h 30.371.0 25.474.3 44.375.2
preTFT4TFT IC75+OHP IC75 48h 6.472.0** 55.274.9** 38.473.3*
H630
Control 38.971.2 24.270.9 36.972.0
OHP IC75 48h 19.877.9 37.173.2 43.175.0
TFT IC75 48h 12.175.7 43.977.1 44.175.9
TFT IC75+OHP IC75 48h 13.673.5 49.172.6* 37.370.9
preTFT4OHP IC75 48h 26.071.4 30.671.9 43.472.9
preTFT4TFT IC75+OHP IC75 48h 11.573.7 52.770.8** 35.873.5
SW1116
Control 46.972.6 23.272.0 29.970.7
OHP IC75 48h 30.571.9 41.773.0 27.871.6
TFT IC75 48h 8.571.1** 35.872.5 55.772.1**
TFT IC75+OHP IC75 48h 12.771.2** 49.272.2 38.172.6*
preTFT4OHP IC75 48h 12.670.8** 36.172.9 51.373.7**
preTFT4TFT IC75+OHP IC75 48h 9.370.3** 50.874.1 39.974.4*
The cells were exposed 48h to [IC75] of OHP, TFT or both drugs. These drug concentrations are mentioned in the legend of Table 2. preTFT: 4h TFT pre-incubation period.
Values are means7s.e.m. (n¼3). Significant differences compared to OHP alone: *Po0.05; **Po0.01.
ERCC1 (36 kDa)
MLH1 (85 kDa)
MSH2 (105 kDa)
Tubulin (50 kDa)
H630 Colo320 WiDr SW1116 SNU–C4
Figure 7 Basal protein levels of the DNA repair enzymes ERCC1, MLH1
and MSH2 for the colorectal cancer cell lines H630, Colo320, WiDr,
SW1116 and SNU-C4. Equal protein amounts from unexposed cells were
used for Western blotting as described in the Materials and Methods
section.
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sxenografts in mice incorporation of TFT into DNA was
significantly higher with divided dosing than single dosing,
resulting in enhanced antitumour activity and no additional side
effects. Regarding the TFT–OHP combination, we observed that
preincubation with TFT resulted in less formation of Pt-DNA
adducts and less subsequent induction of apoptosis than did
simultaneous incubation without preincubation. The exact
mechanism responsible for this decrease in formation of Pt-DNA
adducts remains to be elucidated. Nonetheless, our data suggest
that simultaneous incubation is ideal to maximise anti-tumour
effects.
We studied both fixed and variable drug concentration ratios of
TFT and OHP. Previous studies of drug combinations have often
focused on a fixed ratio between the drug concentrations, but a
fixed ratio does usually not reflect the actual ratio in patients (Van
Moorsel et al, 1999; Temmink et al, 2006). Oxaliplatin and TFT
show comparable growth inhibition curves (Figures 1 and 2),
indicating the same growth inhibition kinetics. The synergism was
observed at FA40.5. Although data at low drug concentrations
suggest antagonism, we do not consider this part of the curve as
relevant, since one aims to expose tumour cells to the highest
possible cytotoxic drug concentration; this means that 25% growth
inhibition is irrelevant, because this would mean that the tumour
cell population still grows at 75% compared to untreated tumour
cells. Our data are favourable for potential future application of
this combination since synergism could be induced for both
combination variants (fixed and variable ratios) for most cell lines.
Trifluorothymidine has a t1/2 of about 15min, but administration
of several doses of TPI together with divided dosing of TFT
increases the AUC and t1/2 dramatically, which in turn could
increase OHP-induced cytotoxicity when given simultaneously
within the same time period. OHP is given by infusion and has a
t1/2 of less than 30min (Ehrsson et al, 2002). This will result in a
variable ratio, and therefore the variable ratio used in our
experiments will better reflect a clinical situation.
Effects of combined OHP and TFT were cell line-dependent. The
most significant results were obtained with the SW1116 cell line,
which is the cell line most resistant to TFT. This is a promising
perspective since combinations are aimed to reduce or bypass
resistance. Trifluorothymidine enhanced OHP-induced cytotoxi-
city by increasng of the formation of Pt-DNA adducts (almost
two-fold), which were well retained. This was accompanied
by enhanced DNA-strand break formation, cell cycle arrest
and subsequent apoptotic cell death, possibly mediated through
caspase-3. Possibly because H630 is far more sensitive to both TFT
and OHP than SW1116, the drug combination showed less
pronounced effects compared with SW1116. The present study
shows that no clear mechanism can be associated with the
sensitivity to OHP or to the synergism between OHP and TFT.
Platinum-DNA (Pt-DNA) adduct formation is enhanced, as well as
DNA damage. However, with the comet assay it is difficult to assess
the real tail moment values below five, and as it is not justified to
add up the tail moments , one can only conclude that DNA damage
is higher in the combination and is highest in the most synergistic
cell line SW1116. In addition, on this cell line, the most
pronounced changes in cell cycle distribution (increased G2M)
were found, possibly adding to the synergistic effect. This might be
due to differences in TS levels or the incorporation rate of TFT in
the cells. The present studies were also performed to see whether
DNA damage repair was of any influence. The Western blot results
showed that the protein expression levels of ERCC1, MLH1 and
MSH2 DNA repair proteins do not correlate with the observed
DNA damage induced by TFT–OHP. This was expected for MLH1
and MSH2 (DNA mismatch repair), which are mainly involved in
the repair of cisplatin-induced DNA damage, not OHP-induced
DNA damage. A possible increase of TFT incorporation into DNA
by OHP might also interfere with the repair of OHP-induced DNA
damage by ERCC1.
In conclusion, the combination of TFT with OHP is synergistic
in colorectal cancer cells, which is related to increased Pt-DNA
adduct formation and retention, cell cycle arrest and DNA damage
induction. Therefore, our in vitro results provide a rationale for a
clinical study of TAS-102 (TFTþTPI) together with OHP, with a
potential value in the (second-line) treatment of colorectal cancer
patients. Furthermore, the approval of the biological agents
bevacizumab (Avastin
s) and cetuximab (Erbitux
s) might also
be of interest for potential TAS-102-involving combinations,
thereby enhancing inhibition of angiogenesis or targeting EGFR,
respectively.
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